Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
Daniil L Stroyakovskiy, Natalya V Fadeeva, Marina P Matrosova, Konstantin G Shelepen, Grigoriy A Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy D Voevodin, Mariya S Shustova, Fedor Kryukov, Daniil L Stroyakovskiy, Natalya V Fadeeva, Marina P Matrosova, Konstantin G Shelepen, Grigoriy A Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy D Voevodin, Mariya S Shustova, Fedor Kryukov
Abstract
Background: BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to compare efficacy and safety of BCD-021 and reference bevacizumab in combination with paclitaxel and carboplatin in a first-line treatment of inoperable or advanced non-squamous non-small-cell lung cancer (NSCLC).
Methods: Patients with no previous treatment for advanced non-squamous NSCLC were randomly assigned 3:2 to BCD-021 or reference bevacizumab and were treated with bevacizumab + paclitaxel + carboplatin. Therapy continued for 6 cycles (every 3 weeks), until progression of the disease or unbearable toxicity. The primary study endpoint was the overall response rate. The study goal was to prove the equivalent efficacy of BCD-021 and reference bevacizumab. Equivalence margins for 95% CI for the difference in the overall response rates were set at [-18%; 18%], for 90% CI for the ratio of overall response rate were set at [67%; 150%].
Results: In total 357 patients were enrolled in the study, 212 in the BCD-021 group and 145 in the reference bevacizumab group. The ORR was 34.63% in the BCD-022 group and 33.82% in the reference bevacizumab group. Limits of 95% CI for the difference in overall response rates between the groups were [-9.47%; 11.09%]. Limits of 90% CI for the ratio of overall response rate between the groups were [79.6%; 131.73%]. For both approaches CI lied within predetermined equivalence margins. Profile of adverse events (AEs) was similar between the groups (any AEs were reported in 86.89% of patients in BCD-021 group and 89.05% of patients in reference group). No unexpected adverse reactions were reported throughout the study. No statistically significant differences regarding anti-drug antibody occurrence rate was found between BCD-022 (n=4; 1.96%) and comparator (n=5; 3.65%). Both drug products showed low occurrence rate and short life of anti-bevacizumab antibodies. Pharmacokinetics assessment after 1st and 6th study drug injection also demonstrated equivalent PK parameters by all outcome measures.
Conclusions: Thus, the results of this study demonstrated therapeutic equivalence of bevacizumab biosimilar BCD-021 and referent bevacizumab drug.
Trial registration: The trial was registered with ClinicalTrials.gov (Study Number NCT01763645, date of registration 09/01/2013).
Conflict of interest statement
The authors declare that they have no competing interests.
© 2022. The Author(s).
Figures
References
- Garcia J, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi: 10.1016/j.ctrv.2020.102017.
- Botrel TE, et al. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis. Lung Cancer. 2011;74(1):89–97. doi: 10.1016/j.lungcan.2011.01.028.
- Orlov SV, et al. Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients. J Clin Oncol. 2014;32(15_suppl):e13500. doi: 10.1200/jco.2014.32.15_suppl.e13500.
- Díaz LP, et al. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncol. 2021;17(19):2529–2544. doi: 10.2217/fon-2020-0923.
- Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
- ICH E10 Choice of control group in clinical trials (CPMP/ICH/364/96). 2001: .
- FDA Briefing Document: Oncologic Drugs Advisory Committee. ABP215, a proposed biosimilar to Avastin (bevacizumab), Amgen Inc. 2017: .
- Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). 2010: .
- Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi: 10.1056/NEJMoa061884.
- Niho S, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362–367. doi: 10.1016/j.lungcan.2011.12.005.
- Johnson DH, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191. doi: 10.1200/JCO.2004.11.022.
- Reck M, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol. 2010;21(9):1804–1809. doi: 10.1093/annonc/mdq020.
- Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues (EMA/CHMP/BMWP/403543/2010). 2012: .
Source: PubMed